Long-term COVID-19 booster effectiveness by infection history and clinical vulnerability and immune imprinting: a retrospective population-based cohort study
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Long-term COVID-19 booster effectiveness by infection history and clinical vulnerability and immune imprinting: a retrospective population-based cohort study
Authors
Keywords
-
Journal
LANCET INFECTIOUS DISEASES
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2023-03-11
DOI
10.1016/s1473-3099(23)00058-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Protection against Reinfection with the Omicron BA.2.75 Subvariant
- (2023) Hiam Chemaitelly et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effectiveness of mRNA-1273 vaccination against SARS-CoV-2 omicron subvariants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5
- (2023) Hung Fu Tseng et al. Nature Communications
- Waning mRNA-1273 Vaccine Effectiveness against SARS-CoV-2 Infection in Qatar
- (2022) Laith J. Abu-Raddad et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effectiveness of mRNA-1273 and BNT162b2 Vaccines in Qatar
- (2022) Laith J. Abu-Raddad et al. NEW ENGLAND JOURNAL OF MEDICINE
- Protection against the Omicron Variant from Previous SARS-CoV-2 Infection
- (2022) Heba N. Altarawneh et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar
- (2022) Laith J. Abu-Raddad et al. NEW ENGLAND JOURNAL OF MEDICINE
- Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar
- (2022) Hiam Chemaitelly et al. Nature Communications
- Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections
- (2022) Heba N. Altarawneh et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune boosting by B.1.1.529 ( Omicron) depends on previous SARS-CoV-2 exposure
- (2022) Catherine J. Reynolds et al. SCIENCE
- Protection of Omicron sub-lineage infection against reinfection with another Omicron sub-lineage
- (2022) Hiam Chemaitelly et al. Nature Communications
- Duration of immune protection of SARS-CoV-2 natural infection against reinfection
- (2022) Hiam Chemaitelly et al. JOURNAL OF TRAVEL MEDICINE
- Protective Effect of Previous SARS-CoV-2 Infection against Omicron BA.4 and BA.5 Subvariants
- (2022) Heba N. Altarawneh et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune Imprinting and Protection against Repeat Reinfection with SARS-CoV-2
- (2022) Hiam Chemaitelly et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effectiveness and durability of BNT162b2 vaccine against hospital and emergency department admissions due to SARS-CoV-2 omicron sub-lineages BA.1 and BA.2 in a large health system in the USA: a test-negative, case-control study
- (2022) Sara Y Tartof et al. Lancet Respiratory Medicine
- A Covid-19 Milestone Attained — A Correlate of Protection for Vaccines
- (2022) Peter B. Gilbert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Characterizing the Qatar advanced-phase SARS-CoV-2 epidemic
- (2021) Laith J. Abu-Raddad et al. Scientific Reports
- SARS-CoV-2 infection is at herd immunity in the majority segment of the population of Qatar
- (2021) Mohamed H Al-Thani et al. Open Forum Infectious Diseases
- Pfizer-BioNTech mRNA BNT162b2 Covid-19 vaccine protection against variants of concern after one versus two doses
- (2021) Laith J Abu-Raddad et al. JOURNAL OF TRAVEL MEDICINE
- mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar
- (2021) Hiam Chemaitelly et al. NATURE MEDICINE
- Immune imprinting and SARS-CoV-2 vaccine design
- (2021) Adam K. Wheatley et al. TRENDS IN IMMUNOLOGY
- SARS-CoV-2 seroprevalence in the urban population of Qatar: An analysis of antibody testing on a sample of 112,941 individuals
- (2021) Peter V. Coyle et al. iScience
- A Systematic Review of the Protective Effect of Prior SARS-CoV-2 Infection on Repeat Infection
- (2021) N. Kojima et al. EVALUATION & THE HEALTH PROFESSIONS
- Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study
- (2021) Noam Barda et al. LANCET
- Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar
- (2021) Hiam Chemaitelly et al. NEW ENGLAND JOURNAL OF MEDICINE
- Why Test for Proportional Hazards?
- (2020) Mats J. Stensrud et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Influenza vaccine effectiveness against all-cause mortality following laboratory-confirmed influenza in older adults, 2010-2011 to 2015-2016 seasons in Ontario, Canada
- (2020) Hannah Chung et al. CLINICAL INFECTIOUS DISEASES
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
- (2020) Fernando P. Polack et al. NEW ENGLAND JOURNAL OF MEDICINE
- Paradoxical clade- and age-specific vaccine effectiveness during the 2018/19 influenza A(H3N2) epidemic in Canada: potential imprint-regulated effect of vaccine (I-REV)
- (2019) Danuta M Skowronski et al. Eurosurveillance
- Using Big Data to Emulate a Target Trial When a Randomized Trial Is Not Available: Table 1.
- (2016) Miguel A. Hernán et al. AMERICAN JOURNAL OF EPIDEMIOLOGY
- Ignoring the matching variables in cohort studies - when is it valid and why?
- (2013) Arvid Sjölander et al. STATISTICS IN MEDICINE
- Seasonal Influenza Vaccine and Increased Risk of Pandemic A/H1N1‐Related Illness: First Detection of the Association in British Columbia, Canada
- (2010) Naveed Z. Janjua et al. CLINICAL INFECTIOUS DISEASES
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search